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Altered synovial fibroblast (SF) transcriptional activity is a key factor in the disease progression of rheumatoid arthritis (RA). To determine the
transcriptional regulatory network associated with SF response to an RA proinflammatory stimulus we applied a CARRIE reverse engineering
approach to microarray gene expression data from SFs treated with RA synovial fluid. The association of the inferred gene network with RA
susceptibility was further analyzed by a case–control study of promoter single-nucleotide polymorphisms, and the presence of epistatic
interactions was determined using the multifactor dimensionality reduction methodology. Our findings suggest that a specific NF-κB
transcriptional regulatory network of 13 genes is associated with SF response to RA proinflammatory stimulus and identify a significant epistatic
association of two of its genes, IL6 and IL4I1, with RA susceptibility.
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Genetic susceptibilityRheumatoid arthritis (RA) is a chronic inflammatory
disease with a prevalence of approximately 1% that primarily
affects diarthrodial joints, in which synovial inflammation
leads to cartilage and bone destruction. The synovial mem-
brane, a rather acellular tissue in normal conditions, becomes
hypertrophic and is composed mainly of synovial fibroblasts
(SFs) [1]. SFs in RA display an activated phenotype, which
significantly contributes to disease initiation and progression
[2,3]. Although several transcription factors like AP-1 [4],
NF-κB [5], or p53 [6] have been previously associated with SF
altered activity, no precise transcriptional regulatory network
has been associated with RA pathophysiology. With the advent
of microarray technology, global gene expression data can now⁎ Corresponding author. Fax: +34 93 489 4015.
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doi:10.1016/j.ygeno.2007.03.011be used to model transcriptional networks associated with
molecular disease mechanisms.
Modeling transcriptional regulatory networks is considered a
reverse engineering problem. By reverse engineering we
understand the process of determining the structure of a system
by reasoning backward from observations of its behavior [7].
Different methods have been recently described to determine
functional networks from microarray gene expression data.
After providing success with lower eukaryotes [8] they are also
proving successful in defining regulatory networks in the first
studies with human gene expression data [9].
Microarray analysis of cultured SFs treated with a single
factor can be useful to study molecular mechanisms relevant
to RA [10,11]. However, the synovial environment in RA is
extremely complex, with the interplay of cytokines, chemo-
kines, matrix-degrading enzymes, growth factors, and immune
Table 1
Three-fold differentially expressed genes in cultured synovial fibroblasts after
RA synovial fluid treatment
Accession
No.
Gene Description Fold
change a
NM_016584 IL23A Interleukin 23, α subunit p19 7.9
NM_000641 IL11 Interleukin 11 6.7
NM_006329 FBLN5 Fibulin 5 5.7
NM_000963 PTGS2 Prostaglandin-endoperoxidase synthase 2
(prostaglandin G/H synthase and
cyclooxygenase)
5.4
NM_000759 CSF3 Colony stimulating factor 3
(granulocyte)
4.4
NM_000675 ADORA2A Adenosine A2a receptor 4.1
AK058127 — Homo sapiens cDNA FLJ25398 3.8
NM_000758 CSF2 Colony stimulating factor 2
(granulocyte–macrophage)
3.7
NM_005623 CCL8 Chemokine (C–C motif) ligand 8 3.6
NM_001432 EREG Epiregulin 3.6
NM_006443 C6orf108 Chromosome 6 open reading frame 108 3.6
NM_002192 INHBA Inhibin, βA (activin A, activin ABα
polypeptide)
3.5
NM_000346 SOX9 SRY (sex determining region Y)-box 9
(campomelic dysplasia, autosomal
sex-reversal)
3.5
NM_033035 TSLP Thymic stromal lymphopoietin 3.4
NM_031437 RASSF5 Ras association (RalGDS/AF-6) domain
family 5
3.4
NM_021724 NR1D1 Nuclear receptor subfamily 1, group D,
member 1
3.3
NM_004049 BCL2A1 BCL2-related protein A1 3.2
NM_002089 CXCL2 Chemokine (C–X–C motif) ligand 2 3.1
NM_001682 ATP2B1 ATPase, Ca2+ transporting, plasma
membrane 1
3.0
NM_002692 POLE2 Polymerase (DNA directed), ε2
(p59 subunit)
–3.1
NM_001684 ATP2B4 ATPase, Ca2+ transporting, plasma
membrane 4
–3.1
NM_139314 ANGPTL4 Angiopoietin-like 4 –3.2
NM_000331 SAA1 Serum amyloid A1 –3.2
NM_006283 TACC1 Transforming, acidic coiled-coil-
containing protein 1
–3.3
NM_002084 GPX3 Glutathione peroxidase 3 (plasma) –3.4
NM_012242 DKK1 Dickkopf homolog 1 (Xenopus laevis) –3.8
NM_006006 ZBTB16 Zinc finger and BTB domain
containing 16
–4.5
a p<0.00001.
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factors like TNF and IL1β can regulate gene transcription via
convergent signaling pathways. Synovial fluid is known to
contain most of the proinflammatory factors associated with RA
pathophysiology. Thus we hypothesize that SF in vitro
treatment with a complex proinflammatory stimulus like RA
synovial fluid can help to identify the specific SF transcriptional
network associated with this disease.
Transcriptional regulatory networks are theoretically prone
to the presence of epistatic effects [13]. Epistasis, or more
specifically, genetic epistasis, can be defined as the noninde-
pendent effect of genetic polymorphisms over a particular trait
in an individual [14]. Until now, the analysis of epistatic effects
on human diseases has been limited by the exponential number
of combinations to be analyzed in multilocus models. Recently,
however, data mining approaches for dimensionality reduction
in the analysis of gene×gene and gene×environment interac-
tions have proven useful in the detection and characterization of
epistatic effects in human diseases [13,15].
The present study was therefore designed to determine, first,
whether a particular transcriptional regulatory network is
involved in SF response to RA synovial fluid stimulation and,
second, whether promoter polymorphisms in the genes of this
network are associated with susceptibility to RA via epistatic
interactions. To answer these questions we studied the
differential gene expression profiles from cultured synovial
fibroblasts with and without RA synovial fluid stimulation. We
applied CARRIE, a new method of transcriptional network
ascertainment that couples gene expression analysis with
promoter sequence information to infer regulatory relationships
[16], to the results. After defining the associated transcriptional
network, we analyzed the presence of epistatic interactions
associated with RA susceptibility between promoter single-
nucleotide polymorphisms (SNPs) from the coregulated genes
by using the multifactor dimensionality reduction (MDR)
method [17].
Results
Differentially expressed genes and significant Gene Ontology
(GO) terms
Using conservative criteria for differential expression we
obtained a total of 157 genes differentially expressed between
treatment groups (Supplementary Table S1). A partial list
(fold change >3) of differentially expressed genes is shown
in Table 1.
To evaluate the global gene expression changes on SF in
response to an RA synovial fluid stimulus we compared GO
terms from differentially expressed genes. Statistically over-
represented GO terms (p<0.05) were immune response (GO:
0006955), response to biotic stimulus (GO: 0009607), defense
response (GO: 0006952), receptor binding (GO: 0005102),
cytokine activity (GO: 0005125), and response to wounding
(GO: 0009611). The complete list of genes associated with each
differentially expressed GO can be found in Supplementary
Table S2.Analysis of transcriptional regulatory networks
Determination of significant transcription factor matrices
We determined those transcription factors that most likely
control the response of SFs to RA synovial fluid using CARRIE.
We found that, from all significant matrices (Fig. 1), the NF-κB
distribution matrix stands out as the most clearly associated.
NF-κB has a p value four orders of magnitude more significant
than the immediate associated transcription factor (TF).
Determination of NF-κB regulatory network
We inferred the transcriptional regulatory network of NF-κB
involved in the SF response to RA synovial fluid using
CARRIE (Fig. 2). Although no significant expression change
was observed for NF-κB itself, a significant relationship with 13
Fig. 1. Detection of the TF responsible for gene expression changes in SF treated
with RA synovial fluid. Each horizontal bar represents the log10 p value for
overabundance for a specific TF. Only the 15 most significant TFs are plotted.
8 A. Julià et al. / Genomics 90 (2007) 6–13coregulated genes was assessed. Of these, 11 were up-regulated
by NF-κB action, whereas 2 were down-regulated.
Population-based association analysis of NF-κB-coregulated
genes
To evaluate the association of the regulatory regions of the 13
genes included in the NF-κB network we genotyped SNPs from
or near to the proximal promoter. We finally analyzed a total of
22 SNPs, listed in Table 2. We found all polymorphisms to be in
Hardy–Weinberg equilibrium (p>0.001, data not shown). From
all polymorphisms tested rs1290754 (IL4I1), rs2633958
(COL7A1), rs4694636 (IL8), and rs344589 (CD70) were
associated at p<0.05 although significance was not maintained
after Bonferroni correction. We found strong pairwise linkage
disequilibrium (LD) between markers from the same genetic
region (D′>0.98), except for CD70 (D′=0.78). None of the
estimated multimarker haplotypes was significantly associated
with RA (Table 2).Fig. 2. Inferred transcriptional regulatory network mediating SF response to RA proin
expressed) and its target genes represent direct regulation predicted by ROVER. Th
inhibitory relationships.Genetic epistasis analysis of NF-κB-coregulated genes
We analyzed the presence of epistatic interactions evaluating
all possible two- to seven-way SNP combinations. From these,
the two-SNP combination of rs1290754 (IL4I1) with rs1800797
(IL6) was the best model for RA risk prediction (Fig. 3, left).
The testing accuracy of the selected model was 0.599 (p<0.02
based on a 100-fold permutation test). The odds ratio for this
model was 2.23 (95% CI 1.51, 3.28). Notably, when these two
SNPs were merged as a single variable and the data reanalyzed
it clearly came out as the best model, with a testing accuracy of
0.6 and a cross-validation count of 10 of 10 (Fig. 3, right). The
entropy analysis [18] of the interaction between SNPs (Fig. 4)
clearly shows the strong synergistic interaction between these
two SNPs.
Discussion
This study shows that a particular transcriptional regulatory
network is involved in SF response to RA synovial fluid
stimulation. We found that from all transcriptional networks
analyzed, the NF-κB regulatory network is markedly signifi-
cant. In contrast, other known networks, like AP-1 or p-53,
seem to have a secondary role in the response to this complex
proinflammatory stimulus.
This study also shows that polymorphisms in genes of this
transcriptional network are associated with susceptibility to RA
via epistatic interactions. We found that high-order interactions
between SNPs from IL4I1 (rs1290754) and IL6 (rs1800797) are
significantly associated with risk to develop RA.
NF-κB transcriptional network
NF-κB is one of the TFs most strongly associated with RA
pathogenesis, regulating the activities of many different genes
in many cell types [19,20]. We determined a highly statistical
overrepresentation of NF-κB binding sites in the promoter
regions of the coregulated genes (p<1×10−9, Fig. 1). In this
model, NF-κB is not differentially expressed, which is inflammatory stimulus. Solid arrows between NF-κB (i.e., in red, not differentially
e “+” symbols represent stimulatory relationships and the “−” symbols denote
Table 2
Association analysis of promoter SNPs of NF-κB transcription regulatory network genes
Gene Accession
No.
SNP MAF-Hap MAF p-Genot a p-Allelea p-Haploa
FAM5B NM_021165 rs2049162 0.06 0.04 0.58 0.37 0.95
FAM5B NM_021165 rs6665358 0.04 0.04 0.68 0.46 —
FAM5B NM_021165 rs725416 0.18 0.17 0.42 0.57 —
IL4I1 NM_152899 rs1290751 0.42 0.47 0.65 0.52 0.7
IL4I1 NM_152899 rs1290754 0.46 0.41 0.028 0.96 —
COL7A1 NM_000094 rs1264194 0.36 0.31 0.5 0.94 0.08
COL7A1 NM_000094 rs2633958 0.05 0.06 0.026 0.016 —
SAA1 NM_000331 rs1533723 0.22 0.35 0.78 0.58 0.68
SAA1 NM_000331 rs874957 0 0.35 0.67 0.44 —
IL8 NM_000584 rs2227306 0.34 0.37 0.08 0.23 0.26
IL8 NM_000584 rs4694636 0.42 0.4 0.06 0.04 —
IL6 NM_000600 rs1800797 0.48 0.38 0.28 0.94 —
CSF3 NM_000759 rs2227321 0.34 0.36 0.42 0.48 —
CD70 NM_001252 rs344589 0.21 0.14 0.034 0.028 0.06
CD70 NM_001252 rs168259 0.19 0.12 0.41 0.46 —
CXCL1 NM_001511 rs3117600 0.29 0.31 0.11 0.75 —
CXCL2 NM_002089 rs3806792 0.34 0.41 0.48 0.32 —
CXCL3 NM_002090 rs370655 0.36 0.41 0.91 0.72 —
IL1F9 NM_019618 rs13014143 0.48 0.44 0.92 0.98 0.98
IL1F9 NM_019618 rs13392494 0.15 0.16 0.57 0.8 —
TRIB3 NM 021158 rs6139007 0.18 0.22 0.45 0.3 0.66
TRIB3 NM 021158 rs6084242 0.33 0.36 0.1 0.46 —
MAF-Hap, minor allele frequency in HapMap Caucasian European samples; MAF, minor allele frequency in Spanish hypernormal controls; p-Genot, p value for
genotypic test; p-Allele, p value for allelic test; p-Haplo, p value for haplotypic test.
a Nominal p values, not corrected for multiple tests (in bold p<0.05). All SNPs demonstrated Hardy–Weinberg p values >0.001.
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the posttranscriptional level through IκB phosphorylation and
degradation [21]. Strikingly, however, we found a clear cutoff
between NF-κB and the rest of the TFs (i.e., four orders of
magnitude with the second most associated TF). Since synovial
fluid is a complex mixture of various stimulating proinflamma-
tory factors we would rather expect a less pronounced main TF
prediction. It is even more striking if we compare the similarity
between this result and the results obtained using the same
inference methodology in yeast perturbation experiments [16].
In these studies different single-factor stimulation experiments,Fig. 3. Summary for IL4I1 (rs1290754) and IL6 (rs1800797) promoter SNP combin
single merged variable. High-risk combinations appear as dark gray and low-risk com
and the right bar represents the frequency in controls.from which the main TF was already known, were used to
validate CARRIE methodology.
In the present study we determined a specific transcriptional
regulatory network of 13 genes for which there is evidence
supporting their roles in SF NF-κB-mediated response in RA.
CXCmotif chemokines—CXCL1, CXCL2, CXCL3, and IL8—
are regulated by NF-κB [22,23], are overexpressed by TNF and
IL1β stimulation [24], and have been demonstrated to be
overexpressed in RA fibroblasts [22]. Similarly CSF3, IL1F9,
CD70, and COL7A1 can be activated in RA fibroblasts or
other cell types after TNF and IL1β stimulation [24–27] or inations associated with risk to RA as (left) independent variables and as (right) a
binations as light gray: the left bar in the boxes represents the frequency in cases
Fig. 4. Dendrogram of interactions between NF-κB transcription regulatory network polymorphisms. The colors used depict the degree of synergy, ranging from red
(highest information gain) to blue (highest information redundancy). Note that for the interaction between IL4I1 (rs1290754) and IL6 (rs1800797) promoter SNPs, the
degree of synergy (gain of information) between them is highest.
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cytokines in RA and which is clearly associated with RA fibro-
blast altered expression, has a demonstrated NF-κB-induced up-
regulation [29], together with IL4I1 [30], TRIB3 [31], and
SAA1 [32]. The latter, however is significantly down-regulated
in our study, an effect for which we have no explanation. Finally,
FAM5B (i.e., BMP/retinoic acid-inducible neural-specific pro-
tein) is a recently characterized gene with a perforin-like
conserved domain structure [33] and, to our knowledge, this
study is the first evidence for NF-κB transcriptional control.
IL4I1×IL6 epistatic model for RA risk
Several lines of evidence point to the relevance of epistatic
effects in RA etiology. The most compelling data come from
quantitative trait analysis on mouse [34] and rat [35,36] RA
models. Although epidemiological modeling studies of the
disease have provided the theoretical framework for epistasis in
RA [37], very few studies have analyzed the presence of such
interactions in humans [38,39]. One of the reasons for the lack
of these studies is the statistical and computational challenge
that is associated with the analysis of genetic polymorphism
combinations and disease susceptibility [18]. The multifactor
dimensionality reduction approach used in this study attempts to
address this limitation and is able to determine the multilocus
combinations associated with high risk to develop disease [13].
Analysis of main effects in the IL4I1 promoter SNPs showed
a modest association at the genotypic level for rs1290754
(p<0.05, Table 2) although not significant after Bonferroni
correction (data not shown). To our knowledge, this is the first
study to analyze the association between IL4I1 gene poly-
morphisms with RA. On the other hand, IL6 polymorphisms
association with RA have already been studied in the Spanish
population [40] and, in agreement with this previous study, we
did not detect a significant main effect after allelic and
genotypic analysis (Table 2). However, by analyzing the high-
order interactions between all candidate polymorphisms and
RA using MDR we identified a significant interaction between
IL6 promoter SNP rs1800797 and IL4I1 promoter SNPrs1290754 (OR 2.2; 95% CI 1.5109, 3.2806; p<0.02). Even
after merging both SNPs as a unique variable, it is still the
model (i.e., single variable model in this case) with the highest
testing accuracy (Fig. 3).
How does this epistatic effect increase the susceptibility to
develop RA? While IL6 is a well-known proinflammatory
cytokine clearly associated with RA pathology, the role of IL4I1
in RA still needs to be explored. One intriguing evidence that
could support the active role of this protein in RA pathophy-
siology could be its identification as an autosomal H locus [41].
H loci are minor histocompatibility antigens that are processed
by MHC class I and class II molecules and that can be
responsible for allograft rejection in transplant therapies.
Studies in mice found that the H46 locus, containing Il4i1
(i.e., the murine homologue of IL4I1), synthesizes a peptide that
is presented by MHC class II that has the potential to elicit
CD4+ T cell responses in autoimmunity. Autoantigen activation
of T cells is one of the main models for the etiology and
pathogenesis of RA [12]. The interaction dendrogram method
implemented in MDR software (Fig. 4) allowed us to determine
the nature of the interaction as a high-degree synergy between
IL6 and IL4I1 promoter polymorphisms. Thus, it is tempting
to speculate that high-risk combinations in this two genes could
led to the proactive role of the synovial fibroblast in the devel-
opment of RA.
Limitations of the approach
In our view, the scope of the study could be limited mainly in
two ways. First, is the stimulation of synovial fibroblasts with
RA synovial fluid a valid model to study RA pathophysiology?
Second, is CARRIE a valid reverse engineering approach to
characterize relevant transcriptional regulatory networks in
human disease?
RA synovial fluid is formed by the secretions of multiple
activated immune and nonimmune cells, which give rise to a
complex proinflammatory environment that contributes to the
progression of disease. Thus, the transcriptional profiling of SF
stimulated with RA synovial fluid should yield more valuable
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cytokine stimulation. Accordingly, several significantly differ-
entially expressed genes we have detected, like INHBA [42],
IL11 [43], PTGS2 [44], IL6 [22], or IL23A [45], have been
previously associated with RA synovial pathophysiology (Table
1 and Supplementary Table S1). Furthermore, by using this
experimental model we have been able to identify a two-loci
epistatic interaction that is significantly associated with sus-
ceptibility to developing RA.
Reverse engineering is a new kind of analytical approach that
has been only recently used with human data [9]. For this study
we have made the assumption that the inference method im-
plemented in CARRIE can efficiently model the transcriptional
regulatory network associated with SF response to an RA
synovial fluid stimulus. One of the limitations of this metho-
dology is that it is subject to the completeness of the TRANS-
FAC human database. Therefore, statistical error could have
been introduced by absent position-specific scoring matrices
(PSSMs) or weak promoter binding sites. However, the highly
significant statistical association of the NF-κB transcriptional
regulatory network and the previous implication of several of its
genes in RA pathophysiology give strong support to the
effectiveness of this methodology. To our knowledge, this is
the first study to apply CARRIE methodology on human data.
Conclusion
In summary, this study shows that a specific NF-κB
transcriptional regulatory network is significantly associated
with synovial fibroblast response to RA synovial fluid and that
an epistatic interaction between two of its genes, IL6 and IL4I1,
is significantly associated with the risk of developing RA.
Although other relevant SF regulatory networks cannot be
excluded in RA pathophysiology, it is the first demonstration of
a transcriptional regulatory network associated with this
disease. We believe that the definition of relevant transcriptional
networks by reverse engineering can greatly accelerate the
search for disease susceptibility genes.
Materials and methods
Cell culture and synovial fluid
Osteoarthritis (OA) SFs have been widely used as a reference for the
experimental study of synovial membrane. In this study, synovial membrane was
obtained from an OA patient undergoing knee joint replacement surgery. The
membrane was thoroughly minced to∼1mm3 and incubated for 2 h at 37°C with
1 mg/ml collagenase I A (Sigma, Spain) under continuous agitation. Cells were
pelleted and cultured in DMEM with L-glutamine (Gibco Life Technologies,
Spain) with 10% FCS and penicillin–streptomycin (50 IU/ml) (Gibco Life
Technologies, Spain) at 37°C with 5% CO2 in a humidified atmosphere.
Synovial fluid was obtained from an inflamed knee joint of a 55-year-old RA
female patient in a sterile nonheparinized tube. From the time of extraction to
centrifugation (1500g, 10 min) the sample was continuously kept at 4°C. The
acellular supernatant was kept at −20°C until cell treatment.
Synovial fibroblast stimulation and microarray analysis
After the third passage, the synovial cell culture was divided into control and
treatment groups. Control cells were cultured with fresh medium (DMEM)without FCS, whereas treated cells were cultured in a fivefold diluted synovial
fluid (80% DMEM). After 12 h of treatment, total RNAwas extracted from both
cell groups using a column affinity purification method (RNeasy; Qiagen,
Spain). For each class three RNA samples were obtained and analyzed
separately in Human IA CodeLink Expression Bioarrays (General Electric
Healthcare, Spain) representing ∼20K UniGene entries. Briefly, each RNAwas
in vitro amplified, hybridized, stained, and scanned using the manufacturer’s
instructions. Signal and background intensities were also extracted using the
manufacturer’s recommended software (CodeLink version 2.3.2). Normal-
ization of background-corrected intensities was performed stepwise: intraclass
replicates were normalized using cyclic lowess normalization and both classes
were finally normalized using quantile normalization. Data transformation and
normalization were carried out using the libraries provided as part of the R
statistical language package version 2.1.0 (http://cran.r-project.org). Primary
data and supplementary tables can also be accessed at http://www.urr.cat.
Differential gene expression and gene ontologies
Differentially expressed genes in fibroblasts stimulated with RA synovial
fluid compared to controls were identified using the two-sample Welch t statistic
implemented in Bioconductor’s “multtest” package (http://www.bioconductor.
org). To correct for multiple testing, a modified Bonferroni correction procedure
was used. Since for each class we have analyzed RNA samples belonging to the
same biological source (i.e., same individual) we decided to use a more stringent
statistical cutoff as a measure of differential expression (i.e., ≥2-fold change in
mRNA abundance, adjusted p value <0.00001).
Functional analysis of differentially expressed genes was performed using
the program GOstat (http://gostat.wehi.edu.au/). Briefly, significantly over-
expressed genes were selected as a test group and underexpressed genes were
selected as the reference group. GO terms from both groups are then compared
via Fisher’s exact test and approximated p values are computed for each of them.
Since the number of GO terms tested is large, we corrected the nominal p values
using the Bonferroni correction procedure.
Reverse engineering of the transcriptional regulatory network
associated with SF response to synovial fluid using CARRIE
Normalized data and differential expression significance p values were
uploaded into the CARRIE server (http://zlab.bu.edu/CarrieServer/html/).
CARRIE is a computational method for transcriptional regulatory network
inference from microarray analysis using promoter sequence information [16].
Briefly, microarray results are used to discriminate positive (altered expression)
from negative (expressed but constant) groups of genes. From these two
groups, statistically overrepresented TFs whose binding sites are more
abundant in the positive set relative to the negative set are determined using
the ROVER algorithm. Moreover, ROVER also identifies overabundant
promoters that are likely to be regulated by the predicted TFs. All the
information is finally gathered into CARRIE, where a graphical network is
computed highlighting regulatory relationships between TFs with regulated
genes.
We used the same criteria for significant expression change as for differential
expression analysis (i.e., adjusted p<0.00001, fold change ≥2). PSSMs for
human TF binding sites were obtained from the TRANSFAC Professional
version 7.2 database. Promoter sequences for the list genes in CodeLink Human
IA Bioarrays were downloaded using the PromoSer server (http://biowulf.bu.
edu/zlab/PromoSer/) version 3.0 (based on NCBI Build 34). For each gene 2000
bases upstream of the transcription start site (TSS) and 50 bases downstream of
the TSS were retrieved, selecting only the sequence that was closest upstream to
the 5′ end, excluding guessed entries and ignoring promoter region overlaps or
assembly gaps. The frequency of significant binding sites for a single TF in a
random promoter was set to 0.0001 and the cutoff for binding site
overabundance was p=0.001.
Since the TRANSFAC collection of matrices contains, in some cases, many
matrices for a particular TF, we applied redundancy reduction to obtain only the
highest scoring PSSM for each group. Significance values were also corrected
for multiple testing using the default Benjamini and Yekutieli stepped correction
for control of the FDR.
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To increase the power of the sample-based case–control design we used the
hypernormal control group strategy described by Morton and Collins [46].
Hypernormal controls are defined as those individuals with the lowest liability to
develop the disease. By using extreme discordant phenotypes the efficiency of
the association study is usually much greater than with normal controls. The
details of the hypernormal control group (n=181) and the cohort of RA patients
(n=257) are given in Ref. [47]. This study was approved by the ethics
committee of the Institut de Recerca Hospital Universitari Vall d’Hebron.
Gene association study: SNP selection and genotyping
For all 13 genes coregulated in NF-κB transcriptional network we selected
SNPs in or close to their proximal promoter (2000 bases upstream from TSS).
We used Entrez dbSNP (Human Build 35.1) and HapMap (HapMap Public
Release 18) database information to select the most informative SNPs. We used
the following selection criteria: (i) heterozygosity >0.2 in Caucasian European
samples and (ii) in the proximal promoter or in the LD block that encompasses
this region, built under standard definition [48]. In those cases in which the
second criterion did not apply we favored the selection of multiple close SNPs to
increase the informativeness of the locus by building multimarker haplotypes.
Genotyping was done on a MALDI-TOF mass spectrometer (MassArray
System) using the Spectrodesigner software (Sequenom) for primer selection
and multiplexing and the homogeneous mass-extension process for producing
primer extension products. We regenotyped >30% of the samples in cases and
controls with a genotype concordance of 100% between independent runs.
Genotyping was done at the CEGEN, Nodo de Santiago, Santiago de
Compostela, Spain. All primer sequences are available on request.
Population-based association analysis
All association analyses were performed using R (version 2.1.0). Hardy–
Weinberg equilibrium was tested using the Genetics package. Association
analysis of each SNPwas performed using Pearsonχ2 test of the null hypothesis,
and exact p values were obtained by Monte Carlo simulation (2000 replicates).
Haplotype analysis was performed using the Genecounting/Permute program
implemented in the Gap package. Briefly, case–control haplotypes are analyzed
using model-free analysis and permutation tests of allelic association [49].
Genetic epistasis analysis using multifactor dimensionality reduction
We analyzed high-order interactions between NF-κB transcriptional
regulatory network SNPs using the MDR method. MDR is a nonparametric
model-free method designed to analyze gene×gene or gene×environment
interactions [13]. Traditionally, the analysis of such high-dimensional data has
been hampered by the limitations of statistical modeling techniques. MDR
attempts to address this limitation using a data reduction approach called
constructive induction [18]. Basically, multilocus genotypes (n dimensions) are
pooled into a single risk predictor variable with only two dimensions (i.e., high
risk or low risk). The predictive performance of the best model is then assessed
through k-fold cross-validation and its significance determined through Monte
Carlo permutation testing. It is important to note thatMDR assigns a data point as
“unknown” when there are no data points for that genotype combination in the
training set. This becomes of particular relevance for larger n-way combination
analyses, since more contingency-table cells can contain no observations.
The present analysis was performed with the MDR software Beta 1.0.0 RC1
(http://www.epistasis.org/open-source-mdr-project.html). Statistical interpreta-
tion of the significance of the MDRmodel is facilitated by the visualization of an
interaction dendrogram. This dendrogram is built from a hierarchical cluster
analysis of entropy-based measures of interaction information between
polymorphisms.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.ygeno.2007.03.011.References
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